Belimumab for systemic lupus erythematosus: a practice-based view

被引:18
|
作者
Parodis, I. [1 ]
Axelsson, M. [2 ]
Gunnarsson, I. [1 ]
机构
[1] Karolinska Univ Hosp, Rheumatol Unit, Dept Med, S-17176 Stockholm, Sweden
[2] KTH Royal Inst Technol, AlbaNova Univ Ctr, Stockholm, Sweden
关键词
Systemic lupus erythematosus; belimumab; B-lymphocyte stimulator; B-cell activating factor; biologics; B-LYMPHOCYTE STIMULATOR; DISEASE-ACTIVITY; MONOCLONAL-ANTIBODY; TNF RECEPTOR; PLASMA-CELLS; RITUXIMAB; BAFF; CYCLOPHOSPHAMIDE; MANAGEMENT; EFFICACY;
D O I
10.1177/0961203313476154
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with multiple organ involvement. B-lymphocyte activity plays a pivotal role in the development and course of the disease. A newly developed agent called belimumab has recently been approved to treat active, autoantibody positive SLE as an add-on to standard therapy. Specifically binding to soluble B-lymphocyte stimulator protein, it reduces the formation of immunoglobulins and autoantibodies. Its effects have been studied in one phase II and two phase III clinical trials, showing sustained improvement across various clinical indicators and no evidence of increased risk of serious adverse events. Further post-hoc analyses indicate that treatment with belimumab lowers levels of autoimmune antibodies, normalizes low complement and improves SLE activity predominantly in musculoskeletal and mucocutaneous organ domains. Further studies are needed to determine the efficacy of belimumab for patients with severe lupus nephritis and with active involvement of the central nervous system. The introduction of belimumab as the first biological drug approved for the management of SLE likely heralds a surge in the development and use of selectively addressed agents for this heterogeneous and complex disease. Lupus (2013) 22, 372-380.
引用
收藏
页码:372 / 380
页数:9
相关论文
共 50 条
  • [41] Belimumab plasma concentration associated with systemic lupus erythematosus activity
    Moyon, Q.
    Cougnaud, R.
    Mathian, A.
    Cohen, F.
    Pha, M.
    Marin, C.
    Mansour, B.
    Noe, G.
    Amoura, Z.
    Zahr, N.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 158 - 158
  • [42] Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus
    Jordan, Natasha P.
    D'Cruz, David P.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (10) : 1635 - 1645
  • [43] Belimumab: A BLyS-Specific Inhibitor for Systemic Lupus Erythematosus
    Wiglesworth, Amy K.
    Ennis, Kelly M.
    Kockler, Denise R.
    [J]. ANNALS OF PHARMACOTHERAPY, 2010, 44 (12) : 1955 - 1961
  • [44] EFFICACY OF BELIMUMAB TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AT OUR HOSPITAL
    Mizusaki, M.
    Wakiya, R.
    Nakashima, S.
    Shimada, H.
    Sugihara, K.
    Kato, M.
    Miyagi, T.
    Ushio, Y.
    Mino, R.
    Chujo, K.
    Kameda, T.
    Dobashi, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1347 - 1347
  • [45] Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?
    Rua-Figueroa, Inigo
    Altabas-Gonzalez, Irene
    Mourino, Coral
    Roberts, Karen
    Hernandez-Martin, Andrea
    Casafont-Sole, Ivette
    Font-Urgelles, Judit
    Roman-Ivorra, Jose A.
    Navarro, Marta de la Rubia
    Galindo-Izquierdo, Maria
    Salman-Monte, Tarek C.
    Narvaez, Javier
    Vidal-Montal, Paola
    Garcia-Villanueva, Maria Jesus
    Garrote-Corral, Sandra
    Blazquez-Canamero, Maria Angeles
    Fernandez-Cid, Carlos Marras
    Piqueras-Garcia, Maria
    Martinez-Barrio, Julia
    Sanchez-Lucas, Marina
    Cortes-Hernandez, Josefina
    Penzo, Eleonora
    Calvo-Alen, Jaime
    de Dios, Juan Ramon
    Alvarez-Rodriguez, Belen
    Vasques-Rocha, Margarida
    Tomero, Eva
    Menor-Almagro, Raul
    Gandia, Myriam
    Gomez-Puerta, Jose A.
    Frade-Sosa, Beatriz
    Ramos-Giraldez, Consuelo
    Trapero-Perez, Carmen
    Diez, Elvira
    Moriano, Clara
    Munoz-Jimenez, Alejandro
    Pego-Reigosa, Jose Maria
    [J]. RHEUMATOLOGY, 2024,
  • [46] Belimumab, a useful alternative therapy in systemic lupus erythematosus serositis
    Carlos Salman-Monte, Tarek
    Carrion-Barbera, Irene
    Rodriguez Garcia, Eva
    [J]. MEDICINA CLINICA, 2021, 157 (05): : 261 - 262
  • [47] THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Ruperto, Nicolino
    Abud-Mendoza, Carlos
    Viola, Diego O.
    Calvo, Inmaculada
    Levy, Deborah M.
    Gallegos, Julia Calderon
    Ferrandiz, Manuel
    Chasnyk, Vyacheslav
    Keltsev, Vladimir
    Anton, Jordi
    Gastanaga, Maria
    Shishov, Michael
    Boteanu, Alina
    Henrickson, Michael
    Bass, Damon
    Clark, Ken
    Hammer, Anne
    Ji, Beulah
    Nino, Antonio
    Roth, David
    Struemper, Herbert
    Wang, Mei-Lun
    Martini, Alberto
    Lovell, Daniel J.
    Brunner, Hermine
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 764 - 765
  • [48] Adverse Events Associated with Belimumab Therapy in Systemic Lupus Erythematosus
    Ong, Leong Tung
    Chee, Nicholas Ming Zher
    [J]. CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2021, 7 (03) : 272 - 284
  • [50] A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
    Garcia, Alexis
    De Sanctis, Juan B.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (41) : 6306 - 6312